<DOC>
	<DOCNO>NCT02182401</DOCNO>
	<brief_summary>Study investigate pharmacokinetic drug-drug interaction potential BI 207127 NA BI 201335 NA steady-state quantify effect BI 207127 NA , BI 207127 NA combine BI 201335 NA , activity CYP 2C9 CYP 3A4 use probe substrate tolbutamide ( CYP 2C9 ) midazolam ( CYP 3A4 ) .</brief_summary>
	<brief_title>Multiple Doses BI 207127 NA , BI 201335 NA Followed Combination BI 207127 NA BI 201335 NA Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Tolbutamide</mesh_term>
	<criteria>Healthy male ( caucasian ) Age range ≥ 21 ≤ 50 year Body mass index ( BMI ) ≥ 19 ≤ 29.9 kg/m2 Willing complete studyrelated activity Volunteers give write informed consent prior admission study Exclusion criterion : Any find medical examination ( include blood pressure , pulse rate electrocardiogram ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder , clinically relevant electrolyte disturbance Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History photosensitivity recurrent rash History orthostatic hypotension , faint spell blackouts Chronic clinically relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24:00 hour ) within least one month less ten halflives respective drug enrolment study study Use drug might influence result trial 7 day prior enrolment trial trial vulnerable subject ( person keep detention ) exclusion contraindication hypersensitivity midazolam / tolbutamide Participation another trial investigational drug ( within two month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation ( &gt; 100 mL within four week prior administration trial ) Any laboratory value outside reference range indicative underlying disease poor health Excessive physical activity within last week trial trial Hypersensitivity treatment medication and/or relate drug class A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTcF , QTcB interval &gt; 450 m ) Homozygous carrier UGT1A1 ( uridine diphosphate glucuronosyltransferase 1A1 ) enzyme polymorphism *28 *60</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>